Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting

GREENWOOD VILLAGE, Colo., Nov. 14, 2012 /PRNewswire/ --Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction is providing this update on its recent activities ahead of its scheduled shareholder meeting that will take place on December 15, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

"Our goal is to commercialize our extensive drug and patent portfolio to the benefit of our shareholders," said Michael Macaluso, CEO. "We are now entering the pivotal clinical trial phase for the three drugs and one diagnostic device which have most near term promise and will soon either be licensed, sold, partnered or directly distributed by Ampio. Once this is accomplished, we will move up other drugs from our pipeline into the development phase."

The update is as follows:

Ampion

Ampion is a unique anti-inflammatory biologic being developed for the treatment of osteoarthritis of the knee.

Optina

Optina is an orally administered ultra-low dose of danazol for the treatment of diabetic macular edema (DME).

Sexual Dysfunction drugs

This program includes Zertane, for the treatment of premature ejaculation (PE), and Zertane ED, for the treatment of comorbid premature ejaculation and erectile dysfunction (ED).

Read more here:
Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting